BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...

This is a series about the mysteries of internet speak. A fictional offspring of a locust and a hen. Discoveries at sea. A door with an electronic key fob. When something is low-key, but also genuine.

A Brain teaser is a type of puzzle which requires thinking and logical skills. In these types of puzzles, even math riddles are a type of puzzle in which puzzles are in numerical form. These maths ...

Scientists may have pinpointed a way to reverse Alzheimer’s disease in an animal study. The study, led by University Hospitals Cleveland Medical Center, found that restoring a central cellular energy ...

You have “the instincts of an operative, the brains of an analyst: where were you in the mid-90s when I needed you?” spy boss Peter Moira (Brian d’Arcy James) compliments field agent Alexander Hale ...

It's not 'Doomsday' or 'Shang Chi 2,' but Liu will soon kick ass on a a Peacock sci-fi show with Melissa Barrera. Reading time 2 minutes Have you been dying to see more Simu Liu? Well, if so, he’ll ...

A cinematic obsessive with the filmic palate of a starving raccoon, Rob London will watch pretty much anything once. With a mind like a steel trap, he's an endless fount of movie and TV trivia, borne ...

Please provide your email address to receive an email when new articles are posted on . Choline levels were 8% lower in the brains of patients with anxiety disorders. Anxiety disorders were also ...

Every four years at the Cybathlon, teams of researchers and technology “pilots” compete to see whose brain-computer interface holds the most promise. Owen Collumb, a Cybathlon race pilot who has been ...

A non-invasive imaging technique, 1H-MRS, can detect chemicals in different parts of the brain. Choline is represented by “Cho” in the above graph. (SACRAMENTO, CALIF.) — People with anxiety disorders ...

Nuvation Bio has backed off from its plans to directly compare its brain cancer drug to Servier's Voranigo, instead opting to focus on patients who aren’t covered by the approved competitor.

Zenas Biopharma’s autoimmune drug candidate has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. The midstage MoonStone study saw 116 ...